Abstracts tagged "autoantibodies"

Abstract Number: 1573 • 2018 ACR/ARHP Annual Meeting
Salivary Dysbiosis Correlates with Clinical Status of Anti-Ro Positive Mothers of Children with Neonatal Lupus
Robert M. Clancy¹, Carl Langefeld², Hannah C. Ainsworth³, Martin Blaser⁴, Peter M. Izmirly⁵, Corey Lacher¹, Miranda C Marion⁶, Mala Masson¹, Gregg Silverman⁷ and Jill P. Buyon¹, ¹NYU School of Medicine, New York, NY, ²Wake Forest School of Medicine, Winston-Salem, NC, ³Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁴Director of the NYU Human Microbiome Program, NYU School of Medicine, New York, NY, ⁵Rheumatology, NYU School of Medicine, New York, NY, ⁶Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, NC, ⁷Dept of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Neonatal lupus is linked to the presence of circulating anti-Ro antibodies in the mother. These antibodies are present in asymptomatic individuals, who in a…
Abstract Number: 2158 • 2018 ACR/ARHP Annual Meeting
Clinical Significance of Anti-Ro52 Antibody in Chinese Patients with Connective Tissue Diseases: A Single-Center Experience
Si Wu, Xiaojun Tang and Xuebing Feng, Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Autoantibody targeting Ro52 has been implied as a unique antibody with distinct clinical properties. However, its relations with anti-Ro60 antibody and various connective tissue…
Abstract Number: 13 • 2018 ACR/ARHP Annual Meeting
Shared Genetic Origins Among Anti-Proteinase 3 and Anti-Glomerular Basement Membrane Double-Positive Human Autoantibodies
Jeffrey R. Ord¹, Amy G. Clark¹ and Mary H. Foster², ¹Duke University Medical Center, Durham, NC, ²Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Patients with ANCA vasculitis and anti-glomerular basement membrane (GBM) nephritis (Goodpasture’s Disease) develop pathogenic autoantibodies (autoAb) that destroy the microvasculature in lungs and kidneys.…
Abstract Number: 838 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Combined Immunosuppressive Therapy with High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Disease Accompanied By Anti-MDA5-Positive Dermatomyositis -a Multicenter Prospective Study –
Hideaki Tsuji¹, Ran Nakashima¹, Yoshitaka Imura², Masato Yagita², Hajime Yoshifuji¹, Shintaro Hirata³, Takaki Nojima³, Eiji Sugiyama⁴, Kazuhiro Hatta⁵, Yoshio Taguchi⁶, Masaki Katayama⁷, Shuji Akizuki¹, Kosaku Murakami¹, Motomu Hashimoto⁸, Masao Tanaka⁸, Koichiro Ohmura¹ and Tsuneyo Mimori⁹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Clinical Immunology and Rheumatology, The Tazuke-Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan, ³Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ⁴Department of Clinical Immunology and Rheumatology, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ⁵Department of General Medicine, Tenri Hospital, Tenri, Japan, ⁶Department of Respiratory Medicine, Tenri Hospital, Tenri, Japan, ⁷Department of Rheumatology and Clinical Immunology, Osaka Red Cross Hospital, Osaka, Japan, ⁸Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁹Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Interstitial lung disease (ILD) accompanied by anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is often rapidly progressive and associated with poor life prognosis in…
Abstract Number: 1574 • 2018 ACR/ARHP Annual Meeting
Autoantibodies Present in Saliva from Sjogren’s Syndrome and Non-Sjogren’s Sicca Patients Are Not Detectible in Serum
Kristi A. Koelsch^1,2,3, Joshua Cavett^3,4, Kenneth Smith³, Jacen Maier-Moore⁵, Astrid Rasmussen³, David M. Lewis⁶, Lida Radfar⁷, Biji T. Kurien^2,4,8, Judith A. James^3,9, Kathy L. Sivils¹⁰, A. Darise Farris¹¹ and R. Hal Scofield^2,11,12, ¹Section of Endocrinology and Diabetes, University of Oklahoma Health Sciences Center, Okalahoma City, OK, ²U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Clinical Laboratory Science, University of Texas at El Paso, El Paso, TX, ⁶Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁷Department of Oral Diagnosis and Radiology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁸Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma, OK, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: There is evidence for B cell involvement in the pathogenesis of Sjögren’s syndrome by the presence of autoantigen-specific B cells. Autoantibodies toward Ro/SSA and…
Abstract Number: 2288 • 2018 ACR/ARHP Annual Meeting
Preexisting Anti-Acetylcholine Receptor Autoantibodies and B Cell Lymphopenia Are Associated with the Development of Myositis in Thymoma Patients Treated with Avelumab, an Immune Checkpoint Inhibitor Targeting Programmed Death-Ligand 1
Andrew Mammen¹, Arun Rajan², Katherine Pak¹, Tanya Lehky³, Livia Casciola-Rosen⁴, Renee Donahue², Lauren Lepone², Anastasia Zekeridou⁵, Sean Pittock⁵, Raffit Hassan², Jeffrey Schlom² and James Gulley², ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²NCI, NIH, Bethesda, MD, ³NINDS, NIH, Bethesda, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Neurology, Mayo Clinic, Rochester, MN
Background/Purpose: Immune checkpoint inhibitors (ICIs) enhance the immune response against tumors but may also trigger immune-related adverse events (IRAEs). Myositis following receipt of ICIs is…
Abstract Number: 16 • 2018 ACR/ARHP Annual Meeting
Comprehensive Antibody Profiling Using High Density Peptide Arrays Reveals Novel Citrullinated Protein Targets in Rheumatoid Arthritis Serum Samples
Ken Lo¹, Hanying Li², Eric Sullivan² and Jigar Patel², ¹Technology Innovation, Roche Sequencing Solutions - Madison, Madison, WI, ²Roche Sequencing Solutions - Madison, Madison, WI
Background/Purpose: Autoantibodies against citrullinated proteins are found in 64-89% of rheumatoid arthritis (RA) patients, with a specificity of 88-99%. While citrullinated vimentin, fibrin and histone…
Abstract Number: 1070 • 2018 ACR/ARHP Annual Meeting
Seroreactivity Against Recombinant Citrullinated Myosin Is Associated with Measures of Diastolic Dysfunction in Patients with Rheumatoid Arthritis
Christian Geier¹, Justyna Fert-Bober², Jon T. Giles¹, Cesare Russo¹, Sabahat Bokhari³, Aylin Tugcu¹, Jenny Van Eyk² and Joan Bathon¹, ¹Columbia University, New York, NY, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Cardiology, Columbia University, New York, NY
Background/Purpose: Diastolic dysfunction and heart failure with preserved EF are more prevalent in RA. We have previously shown increased staining for citrullinated substrates in necropsied…
Abstract Number: 1581 • 2018 ACR/ARHP Annual Meeting
Lack of Specificity in Testing for Murine Tissue Specific Autoantibodies for the Diagnosis of Sjogren’s Syndrome
Frederick B Vivino¹, Michael D. George², Chadwick Johr³, Nora Sandorfi⁴, Vatinee Bunya⁵, Giacomina Massaro-Giordano⁵, Andrew Diederich⁶, Brandon Eilberg⁶, Lakshmanan Suresh⁷ and Long Shen⁷, ¹Rheumatolgy Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Ophthalmology, University of Pennsylvania, Philadelphia, PA, ⁶Orthopedic Surgery, University of Pennsylvania, Philadelphia, PA, ⁷Trinity Biotech, Inc., Buffalo, NY
Background/Purpose: A group of murine parotid tissue specific autoantibodies (TSAs) which includes anti-SP1 (salivary protein 1), anti-PSP (parotid secretory protein) and anti-CA6 (carbonic anhydrase) are…
Abstract Number: 2291 • 2018 ACR/ARHP Annual Meeting
Longitudinal Course of the Disease in Anti-Mi2 Patients: More Intense Muscle Weakness, Good Response to Treatment and Progressive Reduction of Autoantibody Titers
Iago Pinal-Fernandez^1,2, Katherine Pak³, Maria Casal-Dominguez^4,5, Wilson Huang⁴, Jemima Albayda⁶, Eleni Tiniakou⁷, Julie J. Paik¹, Christopher A. Mecoli⁸, Sonye K. Danoff⁹, Lisa Christopher-Stine⁹ and Andrew Mammen^3,10, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴NIAMS, NIH, Bethesda, MD, ⁵Johns Hopkins Medical School, Baltimore, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁹Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Autoantibodies targeting the Mi-2 (Mi-2a and Mi-2b) nuclear antigen in patients with dermatomyositis (DM) were first described in 1985. However, little is known about…
Abstract Number: 65 • 2018 ACR/ARHP Annual Meeting
Bacteria-Derived Indole Drives Autoimmune Arthritis By Altering B Cell Glycosylation of Autoantibodies
Widian Jubair¹, Erica Alexeev², Timothy Lemke³, Meagan Chriswell¹, Sean Colgan² and Kristine A Kuhn^1,2, ¹Rheumatology, University of Colorado Denver, Aurora, CO, ²Mucosal Inflammation Program, University of Colorado Denver, Aurora, CO, ³University of Colorado Denver, Aurora, CO
Background/Purpose: Ongoing studies in rheumatoid arthritis (RA) implicate intestinal dysbiosis of bacteria as a contributing factor, though the mechanism(s) by which bacteria influence disease is…
Abstract Number: 1085 • 2018 ACR/ARHP Annual Meeting
Natural Gingerols Inhibit Neutrophil Extracellular Trap Release Elicited By Lupus Autoantibodies
Ramadan A. Ali¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: Recent studies have revealed a role for neutrophils in the pathogenesis of lupus and antiphospholipid syndrome (APS). Indeed, neutrophils are activated by various disease-relevant…
Abstract Number: 1693 • 2018 ACR/ARHP Annual Meeting
Innate, Adaptive, and TNF-Superfamily Immune Pathways Inform a Lupus Disease Activity Immune Index That Characterizes Disease Activity in SLE
Melissa E. Munroe^1,2, Joel M. Guthridge¹, Rufei Lu^1,3, Joseph M. Kheir¹, Bolanle Adebayo¹, Susan R. Macwana¹, Hua Chen¹, Virginia C. Roberts¹, Mohan Purushothaman², Sanjiv Sharma², Teresa Aberle¹, Stan Kamp¹, Cristina Arriens¹, Eliza Chakravarty¹, Katherine Thanou¹, Joan T. Merrill¹ and Judith A. James^4,5, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease marked by immune dysregulation. A comprehensive but cost-effective tool to track relevant mediators of altered…
Abstract Number: 2296 • 2018 ACR/ARHP Annual Meeting
Novel Classification of Idiopathic Inflammatory Myopathies Based on Distinctive Features and Autoantibodies: Analysis of 67 Korean Patients
Sang Wan Chung¹, Su-Jin Yoo², Seong-Wook Kang³, In-Seol Yoo³, Seung-Cheol Shim³, Mihye Kwon⁴, Chung-Il Joung⁴, Jinhyun Kim⁵, Seung-Jae Hong¹ and Yeon-Ah Lee⁶, ¹Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea, Republic of (South), ²Departmen of Internal medicine, Chungnam National University School of Medicine, Daejeon, Korea, Republic of (South), ³Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea, Republic of (South), ⁴Department of Internal Medicine, Konyang University hospital, Daejeon, Korea, Republic of (South), ⁵Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea, Republic of (South), ⁶Rheumatology, Kyung Hee University Hospital, Seoul, Korea, Republic of (South)
Novel Classification Of Idiopathic Inflammatory Myopathies Based On Distinctive Features And Autoantibodies: Analysis Of 67 Korean PatientsBackground/Purpose: Since Bohan and Peter first described their diagnostic…
Abstract Number: 106 • 2018 ACR/ARHP Annual Meeting
Highly Elevated Levels of Anti-Mitochondrial Antibodies in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Richard Moore¹ and Christian Lood², ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: We recently described the phenomenon in systemic lupus erythematosus (SLE) in which mitochondria are extruded into the extracellular space during formation of neutrophil extracellular…

« Previous Page
1
…
3
4
5
6
7
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].